Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock - Wikidata - awgldk - TriplyDB

Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock

Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock

http://www.wikidata.org/entity/Q33919190

about

Advances in antibiotic therapy in the critically ill Pharmacokinetic Changes and Dosing Modification of Aminoglycosides in Critically Ill Obese Patients: A Literature Review Antibiotic stewardship in the intensive care unit.Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study.Therapeutic drug monitoring of amikacin in septic patients.Amikacin pharmacokinetics during continuous veno-venous hemodialysis.Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa.Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art.How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration.Risk factors for aminoglycoside-associated nephrotoxicity in surgical intensive care unit patients.Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearance Optimizing the initial amikacin dosage in adults.Bloodstream infections in the Intensive Care Unit.Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock.Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.Pharmacological considerations for the proper clinical use of aminoglycosides.Year in review 2010: Critical Care--Infection.Rational use of aminoglycosides--review and recommendations by the Swedish Reference Group for Antibiotics (SRGA).Clinical implications of antibiotic pharmacokinetic principles in the critically ill.Aminoglycosides use in patients over 75 years old.Antimicrobial dosing in critically ill patients with sepsis-induced acute kidney injury Nebulized antibiotics in mechanically ventilated patients: a challenge for translational research from technology to clinical care.Therapeutic drug monitoring of anti-infective agents in critically ill patients.Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies.Intracellular Pharmacokinetics of Antibacterials and Their Clinical Implications.Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.Application of guidelines for aminoglycosides use in French hospitals in 2013-2014.Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis.Pharmacokinetics of high-dose nebulized amikacin in ventilated critically ill patients.A study to evaluate the first dose of gentamicin needed to achieve a peak plasma concentration of 30 mg/l in patients hospitalized for severe sepsis.A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study.Pharmacokinetics of ceftiofur in healthy and lipopolysaccharide-induced endotoxemic newborn calves treated with single and combined therapy Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.Initial dosing regimen of vancomycin to achieve early therapeutic plasma concentration in critically ill patients with MRSA infection based on APACHE II score.Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.Optimal aminoglycoside therapy following the sepsis: how much is too much?

P2860

Q26749328-A6F90744-448D-4C74-A007-9AEE85D5310B Q29248398-67CA656B-AD7A-4894-9314-8855FCC8CC99 Q30408712-0B2FBE93-9B5F-4754-8505-3C9DE7B6E664 Q30828312-7BDE0129-61D8-4069-9744-EAFAC41231AC Q33754166-FF1E3158-C67D-4497-9588-0CCA32B53735 Q33939050-AA02446E-DA12-4F30-93CC-224064B0A44E Q34290150-CD18D788-E358-4D0D-ADE1-237D4625FF6C Q34327857-D7856515-E17F-47AB-A25F-2615B6DA4EA8 Q34894900-CDACB5A0-CE82-403B-9708-462B8E664AB0 Q35270646-88C847D6-03EA-4AD4-8F0B-D180AA626C39 Q35533213-F8F60FF1-ADB3-4F5A-94C8-B60B2BA220FF Q35598435-EE9B6621-1D96-425B-810C-788719598FCA Q36089167-8135CB6F-1C2E-41F1-BCA8-63E936D6FFB4 Q36158283-A0CF3247-0147-45C9-BC4E-B59A67C6DC3E Q36913336-8D359620-CA9A-483F-A1F7-416CD5DDB2D7 Q37119964-6FB49A74-910E-43B4-915D-139B7E8C5DB6 Q37389435-0EA2C029-5AC7-4501-B8F4-6246DB349BDB Q37538623-2AF80942-A894-411E-9231-CD89749B099C Q37563029-0C80741C-51E4-44B2-A363-B1F559E56A3C Q37956403-277E8111-9B55-4A75-9D82-97DC696B1598 Q37966018-2217BBB1-08AD-4551-B1F1-9DD7F5B7FCE2 Q38070006-53D50BCF-C85B-40FD-8FD5-B1F7CA20E7CF Q38138835-B85FA36D-C5F3-48CD-B5EB-8D6C244B6E59 Q38192961-D9BC33CA-5090-43EC-BE31-87DFD089CA47 Q38365787-2F23541F-2E66-44DC-9F4D-C4557D9D6979 Q38647453-EDA752CF-49B9-4647-8082-0BD82F529F4D Q38790740-A2E058E7-FD40-4067-B630-82BAE4509AE4 Q38850670-336A5BB3-0107-4423-BEF1-E9F0A8DB72D8 Q39390126-029668BF-125B-49A7-9FE0-17AFF75F4A08 Q40265579-776F1B03-DB77-4E93-B305-C480A1B9F30D Q40378234-D2035F03-F42C-49E3-A945-6DE5A0F1EB8C Q40474926-3D7DF63A-D477-4910-A70A-BE3E2103A495 Q40578444-4DE50F76-4333-494B-A593-422B61A3D8F8 Q40689023-384E418A-1D61-4E81-AC19-3A9537B09C11 Q40809870-6B830853-E41F-4156-85C5-952B0A5BDA4E Q41435865-A28F90D0-D5D4-4BB5-8660-21D99122EE33 Q41516734-B78311C4-2802-4F71-9107-6E639F541396 Q41601693-0545B892-DBCE-451D-AE46-99437A3B6B33 Q41696202-4489A271-1CCD-40FE-B158-D44409329A61 Q41963116-FBB264FF-948B-4C71-A903-D221BA6C5907

P2860

Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock

http://www.wikidata.org/entity/Q33919190

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock

@ast

Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock

@en

type

label

Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock

@ast

Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock

@en

prefLabel

Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock

@ast

Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock

@en

P1433

Q33919190-90CAFF6F-FEFA-4FCC-9DA1-F9DBB3A1C6A8

P1476

Q33919190-657FE36E-2B8B-4318-B435-E75EED2E14E7

P2093

Q33919190-01B065D4-A417-40C7-AED2-350193E77D38

Q33919190-1A96ABC5-5D9F-460B-A3CC-B1662E57507B

Q33919190-1FA1DA32-228C-4DCB-BFDE-17DB73E58D22

Q33919190-79FBDDBF-51F9-4AC4-BA2B-FB3759E06064

Q33919190-7A533ACA-E4E0-41F3-9EA1-F0C5430CF4EE

Q33919190-8A7819A3-60F1-4E96-AD4F-1B978B68E9E4

Q33919190-A2766CAC-0616-4C1D-8B3A-978306149C3E

Q33919190-B0FC7D9D-CA1F-4559-ADC5-8125EC501625

Q33919190-BAAAACEE-5891-497E-AA74-1D67D0729FB0

Q33919190-DE18383F-E67E-41F9-BABE-30E7319C6287

P2860

Q33919190-0574BAD4-6EE4-404D-9E92-E75223554F8F

Q33919190-14317C74-C046-4322-BEDA-DC234151B00C

Q33919190-16FD9D94-7FA3-4503-9346-F397D19D6C59

Q33919190-19256699-A45A-4F6F-9615-F17AFA40014D

Q33919190-1DAFF87E-6B04-4DDA-B443-B947982E2F32

Q33919190-33CDAA08-E95C-4538-AF92-CD680A504AAD

Q33919190-3A4D3EC6-780B-41B0-A7BE-E4C2E31B9D78

Q33919190-494DD6A6-5C21-4860-997D-D0D7EDAC05ED

Q33919190-4B703F7A-BE2A-4566-80CF-D38B0C2C6A77

Q33919190-5ADCCE03-2F22-4398-A13C-59C06E3FF58A

P2888

Q33919190-9C98714D-C989-47FC-B848-7CA508387337

P304

Q33919190-FAD3BF12-D838-44FD-8477-5AE2A66EBF66

P31

Q33919190-FBC1AB88-B1A7-4A68-A33B-FAB432FE437E

P356

Q33919190-A4275A40-50DC-44E7-8228-3D5DF013EB71

P433

Q33919190-1ED78F16-5D7D-4BA7-9680-127A6DC199EC

P478

Q33919190-71F6A7C0-B952-4D95-8DF7-D554A4FB6AF1

P50

Q33919190-4589F674-84D5-42D8-8ECB-CC0316A1C2FD

P577

Q33919190-B2CA03EC-5A61-4A4A-9FE5-84147DDE0E25

P5875

Q33919190-6960DA28-1D2E-42A9-A8F0-BBD8E0940FC3

P6179

Q33919190-622D9E4B-1784-4ED3-8096-DEF2833F26B5

P698

Q33919190-7EEF56AE-E737-47DF-9B8D-2790E3963B10

P921

Q33919190-84680BEA-6886-48C6-BA38-9E9E8A917406

P932

Q33919190-DA10635B-2106-4871-9E4D-823BC6CB23E1

P356

P1433

P1476

Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock

@en

P2093

Brice Layeux

http://www.w3.org/2001/XMLSchema#string

Daniel De Backer

http://www.w3.org/2001/XMLSchema#string

Fabio Silvio Taccone

http://www.w3.org/2001/XMLSchema#string

Frédérique Jacobs

http://www.w3.org/2001/XMLSchema#string

Herbert Spapen

http://www.w3.org/2001/XMLSchema#string

Isabelle Delattre

http://www.w3.org/2001/XMLSchema#string

Pierre Wallemacq

http://www.w3.org/2001/XMLSchema#string

Pierre-François Laterre

http://www.w3.org/2001/XMLSchema#string

Thierry Dugernier

http://www.w3.org/2001/XMLSchema#string

Xavier Wittebole

http://www.w3.org/2001/XMLSchema#string

P2860

Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis

APACHE II: a severity of disease classification system

Prediction of creatinine clearance from serum creatinine

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine

Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria

Effects of obesity on pharmacokinetics implications for drug therapy.

Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections.

Pharmacological principles of antibiotic prescription in the critically ill.

Aminoglycoside dosing weight correction factors for patients of various body sizes.

P2888

P304

R53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/CC8945

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Louis Vincent

P577

2010-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43049212

http://www.w3.org/2001/XMLSchema#string

P6179

1048025212

http://www.w3.org/2001/XMLSchema#string

P698

20370907

http://www.w3.org/2001/XMLSchema#string

P921

P932

2887170

http://www.w3.org/2001/XMLSchema#string